Bone infection beneath a diabetic foot ulcer—diabetic foot osteomyelitis (DFO)—remains one of the most consequential and difficult diagnoses in lower-extremity medicine. Up to 20% of mild-to-moderate and 50–60% of severe diabetes-related foot infections involve bone, and DFO is a major driver of prolonged antibiotic exposure, hospitalization, and lower-extremity amputation. Yet despite its frequency, the diagnosis is far from straightforward: clinical signs are often blunted by neuropathy and ischemia, laboratory markers are non-specific, and imaging findings can lag behind the disease. The 2023 IWGDF/IDSA guidelines on diabetes-related foot infections refined the diagnostic pathway, integrating bedside examination, blood biomarkers, plain radiography, advanced imaging, and—when warranted—bone biopsy.
Why an Accurate Diagnosis Matters
Missing DFO commits patients to ulcer non-healing, recurrent infection, and progressive bone destruction. Over-diagnosing it, however, exposes patients to prolonged antibiotic regimens with attendant adverse events, antimicrobial resistance, and unnecessary surgery. The diagnostic challenge is to combine inexpensive bedside tests with selectively applied advanced imaging and tissue sampling, accepting that no single test is sufficient in isolation.
The Bedside Examination: Starting with Probe-to-Bone
The probe-to-bone (PTB) test is performed by inserting a sterile blunt metal probe through an open ulcer; striking gritty, hard tissue suggests cortical bone exposure. In a pooled meta-analysis by Lam and colleagues (Clinical Infectious Diseases, 2016), PTB demonstrated a sensitivity of approximately 87% and specificity of 83%, with a high negative predictive value that is particularly useful for ruling out DFO in lower-prevalence outpatient settings. The 2023 IWGDF/IDSA guidelines endorse PTB as a key initial test, especially when combined with biomarkers and plain radiographs.
Bedside features that further raise suspicion for bone involvement include an ulcer present for more than 30 days, an ulcer larger than 2 cm² or deeper than 3 mm, exposed bone or palpable bone at the wound base, a “sausage toe” appearance, and an unexplained inflamed or warm toe.
Inflammatory Markers and Imaging
No serum marker is diagnostic in isolation. In a 2024 systematic review and meta-analysis pooling 19 studies and more than 2,800 patients, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT) had pooled sensitivities of roughly 70–72% and specificities of 75–77% (Ansert et al., Wound Repair and Regeneration, 2024). A persistently elevated ESR—particularly above 70 mm/h—substantially raises the likelihood of underlying bone infection in a non-healing ulcer.
Plain Radiographs
Serial plain radiographs remain the recommended first imaging step. Findings such as cortical erosion, periosteal reaction, focal bone loss, or sequestrum formation strongly suggest osteomyelitis, but early disease—within the first 2–3 weeks—may be radiographically silent. Repeating films at 2–4 weeks improves diagnostic yield when clinical suspicion persists.
MRI and Advanced Imaging
When plain films are equivocal but suspicion remains high, magnetic resonance imaging (MRI) is the preferred next step. A meta-analysis in Diabetes Care reported a pooled sensitivity of approximately 90% and specificity of 83% for MRI in detecting DFO, outperforming bone scintigraphy and approaching the accuracy of fluorodeoxyglucose positron emission tomography (FDG-PET) (Lauri et al., 2017). MRI is also helpful for surgical planning by delineating the extent of bone involvement, abscesses, and sinus tracts. FDG-PET/CT and labelled white blood cell scintigraphy are reserved for select cases—such as patients with contraindications to MRI, or those in whom Charcot neuro-osteoarthropathy complicates interpretation.
The Role of Bone Biopsy
Bone biopsy with histopathology and culture remains the diagnostic reference standard and the only reliable way to identify the causative organism and its antibiotic susceptibilities. The 2023 IWGDF/IDSA guidelines issue a conditional recommendation for biopsy when the clinical or imaging diagnosis is uncertain, when empirical antibiotic therapy has failed, or when culture-directed therapy is required because of likely resistant organisms. Recent data support the safety of percutaneous bedside bone biopsy when performed through uninvolved skin by appropriately trained clinicians (Senneville et al., 2023).
Treatment Implications of an Accurate Diagnosis
Diagnostic precision shapes therapeutic strategy. In a landmark randomized trial by Lázaro-Martínez and colleagues (Diabetes Care, 2014), antibiotics alone and conservative surgery yielded similar healing rates (75% vs. 86%) and time to healing in carefully selected patients with neuropathic forefoot DFO without ischemia or necrotizing infection. Subsequent systematic reviews confirm that medical and surgical approaches can both succeed in appropriately chosen cases, with surgical resection generally preferred when infection is extensive, ischemia coexists, or empirical antibiotic therapy has failed.
Key Takeaways
Diabetic foot osteomyelitis is best diagnosed through a stepwise combination of clinical assessment, the probe-to-bone test, inflammatory biomarkers (ESR, CRP, PCT), and serial plain radiographs, with MRI and bone biopsy reserved for cases of diagnostic uncertainty or treatment failure. Following the 2023 IWGDF/IDSA pathway can shorten the time to definitive therapy, reduce unnecessary antibiotic exposure, and improve limb salvage in this high-risk population.
References
- Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Clinical Infectious Diseases. 2023;ciad527.
- Ansert E, Tickner A, Cohen D, Murray W, Gould L. Update of biomarkers to diagnose diabetic foot osteomyelitis: a meta-analysis and systematic review. Wound Repair and Regeneration. 2024;32(3):309–319.
- Lam K, van Asten SAV, Nguyen T, La Fontaine J, Lavery LA. Diagnostic accuracy of probe to bone to detect osteomyelitis in the diabetic foot: a systematic review. Clinical Infectious Diseases. 2016;63(7):944–948.
- Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. Diabetes Care. 2017;40(8):1111–1120.
- Lázaro-Martínez JL, Aragón-Sánchez J, García-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care. 2014;37(3):789–795.
- Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3657.
Comments
